Literature DB >> 9203418

Functions of CD40 on B cells, dendritic cells and other cells.

C van Kooten1, J Banchereau.   

Abstract

CD40 is a cell surface receptor that belongs to the tumor necrosis factor receptor family. It was first identified and functionally characterized on B lymphocytes; however, in recent years it has become clear that CD40 expression is much broader, as it is found on monocytes, dendritic cells, hematopoietic progenitors, endothelial cells and epithelial cells. Although initially identified for its activation properties, CD40 is also able to transduce negative signals in various cell types. It is presently accepted that CD40 plays a critical role in the regulation of immune responses. The past year has seen considerable progress in the identification of intracellular molecules mediating CD40 signaling. Furthermore, it has been established that ligation of CD40 ligand (CD40L) delivers signals to the CD40L bearing cells themselves. Finally, the critical role of CD40-CD40L interactions in the development of various disease states has been fully appreciated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203418     DOI: 10.1016/s0952-7915(97)80078-7

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  105 in total

1.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

2.  Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

Authors:  C Chiodoni; P Paglia; A Stoppacciaro; M Rodolfo; M Parenza; M P Colombo
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 3.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

4.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

5.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 6.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

7.  Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets.

Authors:  H Uronen; R E Callard
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

8.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

Review 9.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

10.  Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM.

Authors:  K C Gilmour; D Walshe; S Heath; G Monaghan; S Loughlin; T Lester; G Norbury; C M Cale
Journal:  Mol Pathol       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.